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Spinal muscular atrophy (SMA) is a common autosomal recessive disorder in humans, caused by homozygous
absence of the survival motor neuron gene 1 (SMN1). SMN2, a copy gene, influences the severity of SMA and
may be used in somatic gene therapy of patients with SMA in the future. We present a new, fast, and highly reliable
quantitative test, based on real-time LightCycler PCR that amplifies either SMN1 or SMN2. The SMN1 copies
were determined and validated in 329 carriers and controls. The specificity of the test is 100%, whereas the sensitivity
is 96.2%. The quantitative analysis of SMN2 copies in 375 patients with type I, type II, or type III SMA showed
a significant correlation between SMN2 copy number and type of SMA as well as duration of survival. Thus, 80%
of patients with type I SMA carry one or two SMN2 copies, and 82% of patients with type II SMA carry three
SMN2 copies, whereas 96% of patients with type III SMA carry three or four SMN2 copies. Among 113 patients
with type I SMA, 9 with one SMN2 copy lived !11 mo, 88/94 with two SMN2 copies lived !21 mo, and 8/10
with three SMN2 copies lived 33–66 mo. On the basis of SMN2 copy number, we calculated the posterior probability
that a child with homozygous absence of SMN1 will develop type I, type II, or type III SMA.
Introduction
With an incidence of 1/6,000 to 1/10,000 and a carrier
frequency of 1/40 to 1/50, spinal muscular atrophy
(SMA) is the second-most-frequent autosomal recessive
disease in Europeans (Pearn 1980). It is a neuromuscular
disorder caused by the degeneration of a-motor neurons
of the spinal cord anterior horns, leading to progressive
atrophy of proximal muscles, paralysis, respiratory fail-
ure, and infant death. Patients with SMA have been clas-
sified into three types, on the basis of age at onset and
clinical severity (International SMA Consortium 1992;
Zerres and Rudnik-Scho¨neborn 1995): type I (MIM
253300) is the most severe form, type II (MIM 253550)
is the intermediate form, and type III (MIM 253400) is
the mildest form.
The SMA-determining gene called the “survival mo-
tor neuron” gene (SMN) is present on 5q13 in two
copies, SMN1 and SMN2, which differ by only five
nucleotide exchanges within their 3′ ends (Lefebvre et
al. 1995; Bu¨rglen et al. 1996). Two of these base-pair
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exchanges, located in exons 7 and 8, allow SMN1 to
be distinguished from SMN2 and currently are used for
direct diagnosis of SMA (for review, see Scheffer et al.
2001). In a summary of 1,122 patients with type I, type
II, or type III SMA, it has been shown that 94% revealed
homozygous absence of SMN1 (for review, see Wirth
2000). Approximately half of the remaining patients
were identified as compound heterozygotes (with de-
letions and intragenic SMN1 mutations), whereas the
other half, without SMN1 mutations, were considered
as distinct genetic entities (Wirth et al. 1999).
Each patient affected with SMA retains at least one
SMN2 copy. An inverse correlation between SMN2 pro-
tein level and SMA severity has been reported in humans
and transgenic SMAmice (Coovert et al. 1997; Lefebvre
et al. 1997; Hsieh-Li et al. 2000; Monani et al. 2000).
However, SMN2 fails to provide complete protection
from SMA due to a single, translationally silent nucle-
otide difference in exon 7 that disrupts an exonic splic-
ing enhancer and causes exon 7 skipping (Lorson et al.
1999; Monani et al. 1999). It has been shown that
SMN2 full-length mRNA can be restored by the splicing
factor Htra2-b1 and the nontoxic drug sodium butyrate
(Hofmann et al. 2000; Chang et al. 2001). Therefore,
prevention of exon 7 skipping by up-regulating the full-
length SMN2 mRNA represents an exciting goal for
SMA therapy.
Since homozygous absence of exon 7 of SMN1 is a
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Table 1
Reproducibility of Real-Time LightCycler Quantitative Analyses of SMN1 and SMN2, on the Basis of 10 Independent PCRs
Test and Subjects SMN1/SMN2
No. of
Ag1-CA/C212
Marker Alleles
No. of
SMN Copies
Minimum/Maximum
Average Values
Mean  SD
Values
Coefficient of
Variation
(%)
SMN1 quantitative test:
Carrier / 3/3 1 .989/1.141 1.072  .044 4.0
Carrier / 3/3 1 .975/1.150 1.060  .056 5.2
Control / 3/3 2 1.912/2.276 2.043  .105 5.1
Control / 4/4 3 2.974/3.307 3.112  .119 3.8
SMN2 quantitative test:
Type I SMA del/ 1/1 1 .902/1.132 1.004  .083 8.2
Type I SMA del/ 2/2 2 1.768/2.136 1.918  .104 5.4
Type I SMA del/ 3/3 3 2.784/3.200 2.998  .136 4.5
Type III SMA del/ 4/4 4 3.694/4.233 3.927  .172 4.3
common variant, SMA carrier testing based on direct
quantitative SMN1 analysis is a major issue. So far,
several different SMN quantitative PCR tests have been
developed that include multiple steps and complicated
procedures that are laborious and subject to errors (Ve-
lasco et al. 1996; McAndrew et al. 1997; Taylor et al.
1998; Wirth et al. 1999; Scheffer et al. 2000).
We therefore developed a fast and highly reliable
quantitative test for either SMN1 or SMN2, on the basis
of real-time PCR on a LightCycler instrument (Roche
Diagnostics). This test allowed us for the first time to
analyze a large number of patients affected with SMA
for their SMN2 copy number and to correlate the
SMN2 copy number with type of SMA and duration
of survival. An important aim of the study was to ex-
amine whether the identification of SMN2 copy number
in a patient with SMA could serve as a prognostic tool.
Subjects, Material, and Methods
Carriers and Noncarriers
One hundred twenty-four carriers (parents of multi-
plex families with SMA) and 65 unaffected sibs of pa-
tients with SMA (noncarriers), as determined by hap-
lotype analyses, were used to validate the SMN1 copy
number by real-time PCR. Furthermore, we used 140
DNA samples from control individuals (38 healthy
spouses of SMA carriers and 102 unrelated unaffected
individuals) to determine the rate of SMN1 duplication
on one chromosome and the SMA carrier frequency.
Patient Samples
The quantification of the SMN2 copy number was
performed on DNA samples from 375 patients with
SMAwho previously have been classified as follows: 188
have type I SMA, 110 have type II SMA, and 77 have
type III SMA (Wirth et al. 1997, 1999). The age of
survival was available from 113 patients with type I
SMA. All patients fulfilled the diagnostic criteria defined
by the International SMA Consortium (1992) and by
Zerres and Rudnik-Scho¨neborn (1995) for proximal spi-
nal muscular atrophy. Informed consent was obtained
from all subjects.
DNA Isolation and Quantification and Haplotype
Analysis
Genomic DNA was isolated from blood samples by
the salting-out method (Miller et al. 1988). DNA was
dissolved in TE4 buffer (10 mM Tris/0.1 mM EDTA
pH 8) and was stored for at least 5 d beforemeasurement
of DNA concentration. Photometric measuring of DNA
was performed on a Gene Quant II (Pharmacia). Only
samples that had a 260 nm:280 nm ratio in the range
1.75–1.85 were used. DNA was diluted first to 20 ng/
ml and then to a final concentration of 5 ng/ml. The exact
measurement of the DNA concentration (withmaximum
deviation of 3%) is the most important prerequisite
for reliable determination of the gene copy number. The
multicopy polymorphic markers Ag1-CA and C212
were used for haplotype analysis, as described elsewhere
(Wirth et al. 1995).
Quantitative Real-Time PCR of SMN1 and SMN2
Copy Numbers
For determination of SMN1 and SMN2 gene dosages,
we established a new quantification assay on the basis of
real-time PCR. The quantification was performed with a
LightCycler instrument (Roche Diagnostics) by use of the
fluorescence-resonance energy-transfer technique. Online
measurements of PCR products were based on the use of
either SYBR Green I or specific hybridization probes la-
beled with 3′-fluorescein and 5′-LightCycler Red 640. The
primers were designed to distinguish between SMN1 and
SMN2, ending on or very close to the nucleotide differ-
ences between SMN1 and SMN2 (italicized letters) in
exon 7 at position 6 and intron 7 at position214. SMN1
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Figure 1 Fluorescence versus cycle number, melting peaks, and sequence of new point mutation in SMN2. a, SYBR Green I fluorescence
plot versus cycle number resulting from amplification of genomic DNA (external standard; st 0.5, st 1, st 2, st 3) of an unaffected individual
carrying two SMN1 copies and homozygous absence of SMN2. In addition, four negative controls (three patients with SMA with homozygous
absence of SMN1 and one water control) were tested. Slope p 4.112, error p 0.0279, and . b, SYBR Green I fluorescence plotrp 1.00
versus cycle number resulting from amplification of genomic DNA (external standard; st 1, st 2, st 4, st 8) of a patient with SMA with four
SMN2 copies and homozygous absence of SMN1. In addition, four negative controls (three normal individuals with homozygous absence of
SMN2 and one water control) were analyzed. Slope p 4.057, error p 0.0469, and . c, Normalized SYBR Green I fluorescencerp 1.00
plot of the external standard (st) for SMN1 and samples of carriers (C) and controls (ctr) with one, two, or three SMN1 copies (c). Each copy
number was detected in three different DNA samples. Slopep3.860, errorp 0.0213, and . d,Normalized SYBRGreen I fluorescencerp 1.00
plot of the external standard (st) for SMN2 and of patients with type I, type II, and type III SMA with one, two, three, or four SMN2 copies.
Slope p  3,819, error p 0.0181, and . e, Melting-curve analysis of SMN2, with hybridization probe indicating the mutationrp 1.00
892GrC. The DNA of the patient with SMA with the homozygous 892GrC mutation in SMN2 shows a lower melting temperature (m/m,
C) than a patient with SMA with the wild-type SMN2 sequence (w/w, C). Patients with SMA with heterozygous genotypeT p 58.0 T p 64.5m m
(w/m) display two peaks. f, New intragenic SMN2 mutation 892GrC in patients with SMA, found by sequencing the DNA samples with
melting peaks at 58.0C. Reverse nucleotide sequences obtained from direct sequencing of genomic PCR products from patients 4437 (hetero-
zygous) and 4929 (homozygous ) for the mutation 892GrC; arrows indicate the positions of the mutation.
was amplified by use of the forward primer tel-
SMNex7forw (5′-TTTATTTTCCTTACAGGGTTTC-3′)
and the reverse primer telSMNint7rev (5′-GTGAAAGTA-
TGTTTCTTCCACgTA-3′). SMN2 was amplified by us-
ing the forward primer cenSMNex7forw (5′-TTTATTT-
TCCTTACAGGGTTTTA-3′) and the reverse primer
cenSMNint7rev (5′-GTGAAAGTATGTTTCTTCCACg-
CA-3′). The hybridization probe detects both SMN1 and
SMN2 and consists of a primer pair with a 3′-fluorescein
(SMN FL: 5′-AATGCTGGCAGACTTACTCCTTAAT-
TTA FL-3′) and a 5′-LightCycler Red 640 (SMN LC:
5′-LCR640 AATGTGAGCACCTTCCTTCTTTTTG-
3′). Lowercase letters indicate mutations introduced to
obtain adequate gene-specific PCR.
The PCR was performed in a total volume of 10 ml,
containing 7.5 ng (for SMN1) or 6 ng (for SMN2) of
genomic DNA, 10 pmol of each primer, 1 ml of Faststart
DNA Kit SYBR Green I (Roche Molecular Biochemi-
cals), 4 mMMgCl2 or Faststart Kit hybridization probes
(Roche Molecular Biochemicals), 4 mM MgCl2 and 2
pmol of each hybridization probe. The PCR conditions
for SMN1 or SMN2 with SYBR Green I were: 95C for
10 min followed by 35 cycles with 95C for 15 s, 58C
for 5 s, 72C for 25 s, and a fluorescent detection step
at 76C for 1 s. During the entire program, we used the
maximum temperature transition rate of 20C/s. This
quantification program was followed by a melting pro-
gram to detect the melting points for every PCR product
for each sample. The analysis was performed with the
second derivative maximum method of the LightCycler
software.
The PCR conditions for SMN1 or SMN2 with hy-
bridization probes were: 95C for 10 min, followed by
35 cycles of 95C for 10 s, 58C for 10 s (in this step,
the measurement takes place), and 72C for 20 s. This
PCR program is followed by a melting curve program
consisting of 15 s of denaturation at 95C, 30 s of an-
nealing at 55C, and a melting and continuous measur-
ing step at 0.1C/s up to 85C. The analysis was per-
formed with the second derivative maximum method of
the LightCycler software.
During the log-linear phase, amplification can be de-
scribed as where N is the numbernNp N (1 E )0 const
of amplified molecules; N0 is the initial number of mol-
ecules; E is the amplification efficiency; and n is the
number of cycles. Since the amplification efficiency dur-
ing the log-phase is constant, the initial concentration
of the sample was calculated on the basis of the above
formula, by use of human genomic DNA (external
standard).
For SMN1, the DNA from a healthy individual with
homozygous absence of SMN2 and two Ag1-CA and
two C212 alleles was used as an external standard. This
individual can be considered to possess two SMN1 cop-
ies. We used 1.5 ml of genomic DNA in concentrations
of 1.25, 2.5, 5, and 7.5 ng/ml, respectively, corresponding
to 0.5, 1, 2, and 3 fictive copies of SMN1.
For SMN2, the DNA of a patient with SMA who had
homozygous absence of SMN1 and four Ag1-CA and
C212 alleles was used as an external standard. This pa-
tient can be considered to possess four SMN2 copies.
Genomic DNA (1.2 ml) was used in concentrations of
1.25, 2.5, 5, and 10 ng/ml, respectively, corresponding
to one, two, four, and eight copies of SMN2. In addition,
for a proper SMN2 standard, five further patients with
SMA with three or four SMN2 copies were chosen and
were compared to one another by defining each of the
DNA samples as standards and the other DNAs as un-
known. By means of this procedure, we were able to
make sure that the initially postulated copy number was
correct. All individuals used as standards and controls
have also been tested by competitive multiplex quanti-
tative PCR (Wirth et al. 1999). The standards were used
to calculate the regression curve. In each experiment, the
reproducibility of the calibration curve was analyzed by
evaluation of the slope and the correlation coefficient of
the curve. Sample concentrations were inferred on the
basis of the regression curve in each experiment. All
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Figure 2 Plot of the average SMN1 values for carriers ( ), noncarriers (unaffected sibs of patients with SMA) ( ), andNp 124 Np 65
controls ( ).Np 140
samples were measured at least twice, by use of inde-
pendent DNA dilutions of 5 ng/ml.
Sequencing of Genomic PCR Products
Mutations within the annealing region of the hybrid-
ization probe were detected by direct sequencing of ge-
nomic PCR products of SMN2 exon 7 of patients 4929
and 4437, amplified by the primers cenSMNex7forw and
cenSMNex7rev. Sequencing was performed on an ABI
Prism 377, according to the manufacturer’s instructions.
Statistical Analysis
A special database in Access (Microsoft) was pro-
grammed for collection of all data for patients with SMA
and their families (personal data, clinical features, and
molecular genetic results, as well as data for direct cal-
culation of mean  SD LightCycler SMN1 and SMN2
values and coefficient of variation (CV). The SPSS pro-
gram package was used to construct the Kaplan-Meier
curves.
Prior probabilities for type I, type II, and type III SMA
were based on cumulative frequencies found in cohorts
of patients with SMA (Hausmanova-Petrusewicz et al.
1985). Odds ratios (ORs) were calculated using the SAS/
STAT software, specifically the procedures FREQ and
LOGISTIC in release 6.11 (SAS Institute 1996), accord-
ing to the method of Hosmer and Lemesshow (2000).
The ORs and their 95% Wald confidence limits were
calculated for type I, type II, and type III SMA and for
one to four copies of SMN2. The OR for one copy was
used as a reference and was fixed to unity. ORs and
prior probabilities were used in a Bayesian fashion to
calculate posterior probabilities for type I, type II, and
type III SMA, depending on the SMN2 copy number.
Results
Establishment of a Real-Time PCR for SMN1 or SMN2
on a LightCycler Instrument
On the basis of real-time LightCycler PCR, we de-
veloped a quantitative test that enables a fast and highly
reliable differentiation between either one to four SMN1
copies or one to four SMN2 copies. To specifically detect
either SMN1 or SMN2, primers were designed that end
on or very close to the nucleotide differences between
SMN1 and SMN2 in exon 7 at position 6 and intron 7
at position 214. To analyze the gene-specific amplifi-
cation, DNA from individuals who carry SMN1 only or
from patients with SMA who carry SMN2 only were
used. The production of gene-specific amplicons (figs. 1a
and 1b) allowed us to use both systems for online
fluorescence resonance energy-transfer measurement:
SYBR Green I and LightCycler hybridization probes la-
beled with 3′-fluorescein and 5′-LightCycler red 640.
Since the data for both systems were almost identical
and the SYBR Green I format is less expensive, we will
present only data based on this PCR format.
The reproducibility of the method was determined in
10 independent PCR reactions on 10 different days. For
SMN1, we used DNA from carriers with one copy or
noncarriers with two or three copies, whereas, for SMN2,
we used DNA from patients with type I, type II, and type
III SMA with one to four SMN2 copies. The number of
SMN1 or SMN2 copies in these individuals were also
determined by the previously reported competitive mul-
tiplex quantitative PCR (Wirth et al. 1999), by haplotype
analysis of the Ag1-CA and C212 marker alleles, and by
quantitative analysis of the SMN genes in further relatives
in three generations. The newly developed method allows
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Table 2
LightCycler Mean Values  SD and CVs of Both SMN1,
Tested in 329 Carriers and Controls, and SMN2, Tested in 375
Patients with Type I, Type II, and Type III SMA
Test and
No. of
Copies Na
Minimum/Maximum
Average Values
Mean  SD
Values
CV
(%)
SMN1:
1 123 .599/1.176 .971.077 7.9
2 198 1.683/2.436 2.053.146 7.1
3 7 2.775/3.410 3.027.200 6.6
4 1 4.035 4.035 …
SMN2:
1 13 .860/1.390 1.146.162 14.0
2 153 1.555/2.466 1.900.174 9.2
3 166 2.518/3.411 2.866.203 7.1
4 43 3.524/4.245 3.863.183 5.0
a No. of individuals.
Figure 3 Diagram of the frequency of patients with type I, type
II, and type III SMA versus SMN2 copy number.
a clear differentiation between one to four SMN1 or
SMN2 copies, without any region of overlap (table 1).
Validity of the Heterozygosity SMN1 Test
This test represents a fast molecular genetic tool for
carrier screening both in families with SMA and in the
general population, as well as for identification of com-
pound heterozygous patients with SMA. A representa-
tive quantitative SMN1 PCR of the external standard
and several unknown samples (carriers and controls) is
shown in figure 1c. To validate the test, we analyzed 124
carriers (parents from multiplex families with SMA) and
65 unaffected sibs of patients with SMA (noncarriers,
according to haplotype analysis). The mean value ob-
tained for each person is plotted in figure 2. Maximum
and minimum average values, mean values  SD, and
CVs are given in table 2. All but 5 of 124 carriers showed
one SMN1 copy, as expected. The remaining five carriers
presented two SMN1 copies. Among the unaffected sibs,
61 of 65 presented two SMN1 copies, whereas the re-
maining 4 carried three SMN1 copies. These data sug-
gest that, in 9 of 254 normal chromosomes (124 from
carriers and 130 from unaffected sibs), two SMN1 cop-
ies are present on one chromosome. To determine the
frequency of two SMN1 copies per chromosome in a
larger population, we analyzed 140 additional individ-
uals from the general population (38 spouses of SMA
carriers and 102 control individuals without muscle
weakness; see fig. 2). Of 140 controls, 4 (2.85%) showed
only one SMN1 copy and therefore were identified as
SMA carriers. This corresponds to a heterozygosity fre-
quency of 1 in 35. Additionally, we identified, in 3 of
140 controls, three SMN1 copies and, in 1 of 140 con-
trols, four SMN1 copies. In summary, 14 (2.6%) of 530
normal chromosomes carry two SMN1 copies per chro-
mosome (table 3).
Quantitative Analyses of SMN2 Copy Number in
Patients with SMA
This fast and highly reliable test allowed us to analyze
a large number of patients with SMA for their SMN2
copy number and to correlate these with the type of SMA
and duration of survival. We analyzed the SMN2 copy
number in 188 patients with type I SMA, 110 patients
with type II SMA, and 77 patients with type III SMA
with both SYBR Green I and the hybridization probe.
In four patients, a discrepancy between the SMN2 copies
determined by the two detection systems was observed.
In addition, in four patients (three heterozygous and one
homozygous), the PCR products detected with hybrid-
ization probes showed a different melting curve (fig. 1e).
Direct sequencing of the SMN2 PCR products in two
patients revealed a point mutation at nucleotide position
892, GrC, that causes an amino acid substitution from
glycine to arginine at codon 287 (G287R) (fig. 1f). The
nucleotide exchange is localized within the annealing
region of the hybridization probe, thereby explaining the
altered melting curves.
The quantitative analysis of the SMN2 copy number
in 375 patients with SMA are given in tables 2 and 3.
In 80% of patients with type I SMA, one or two SMN2
copies were found, 82% of patients with type II SMA
carried three SMN2 copies, and 96% of patients with
type III SMA carried three or four SMN2 copies. How-
ever, ∼20% of patients with type I SMA showed three
SMN2 copies, and none showed four SMN2 copies. Sim-
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Table 3
Distribution of Both SMN1 Copies in Carriers, Noncarriers (Unaffected Sibs of Patients
with SMA), and Controls and SMN2 Copies in Patients with SMA
TEST AND
PATIENT STATUS
DISTRIBUTION, FOR SMN COPY NUMBER
TOTAL1 2 3 4
SMN1:
Carrier 119 (96.0%) 5 (4.0%) 0 (0.0%) 0 (0.0%) 124
Noncarrier 0 (0.0%) 61 (93.8%) 4 (6.2%) 0 (0.0%) 65
Controls 4 (2.9%) 132 (94.3%) 3 (2.1%) 1 (0.7%) 140
Total 329
SMN2:
Type I SMA 13 (6.9%) 138 (73.4%) 37 (19.7%) 0 (0.0%) 188
Type II SMA 0 (0.0%) 12 (10.9%) 90 (81.8%) 8 (7.3%) 110
Type III SMA 0 (0.0%) 3 (3.9%) 39 (50.6%) 35 (45.5%) 77
Total 375
Table 4
Distribution of SMN2 Copy Number in Females and Males of
Patients with Type I, Type II, and Type III SMA
SEX AND DISEASE
DISTRIBUTION FOR
SMN2 COPY NUMBER
TOTAL1 2 3 4
Female:
Type I SMA 7 66 13 0 86
Type II SMA 0 11a 38 1 50
Type III SMA 0 1 15 18 34
Male:
Type I SMA 6 72 24 0 102
Type II SMA 0 1a 52 7 60
Type III SMA 0 2 24 17 43
a Significant difference between females and males: ORs (95%Wald
confidence intervals) are, for females, 0.085 (0.037, 0.197) and, for
males, 0.007 (0.001, 0.053).
ilarly, among patients with type II SMA, ∼11% showed
two SMN2 copies, and ∼7% showed four SMN2 cop-
ies, whereas, among patients with type III SMA, none
showed one SMN2 copy, and ∼4% revealed two SMN2
copies (fig. 3).
A strong correlation between SMN2 copy number and
SMA phenotype was observed; however, this correlation
is not absolute. This may be because of (1) true variation
caused by modifying genes or other external factors, (2)
intragenic mutations within SMN2, or (3) SMN2 genes
partially deleted or duplicated as a result of deletions or
gene conversions involving either the 5′ end or the 3′ end
of the SMN genes. To verify the first hypothesis, we
analyzed 13 families with SMA that had siblings car-
rying homozygous mutations of SMN1 but discordant
phenotypes (Helmken et al. 2000a, 2000b). In each case,
identical numbers of SMN2 copies were determined in
haploidentical siblings. Although, in all these families,
the unaffected or milder affected siblings were females,
there is no overall significant difference in the distri-
bution of SMN2 copies between sexes (table 4). For the
second hypothesis, we already presented in this article
an intragenic SMN2 mutation in exon 7 (G278R), re-
vealing that intragenic mutations may indeed be a reason
that can disturb the correlation between SMN2 copy
number and SMA phenotype. To verify the third hy-
pothesis, we analyzed, in our patients with SMA Ag1-
CA and C212—two highly polymorphic markers local-
ized at the 5′ end of the SMN genes (Wirth et al.
1995)—and correlated the total number of marker al-
leles in each individual with the SMN2 copy number
(table 5). In 80% of patients with type I SMA, 77% of
patients with type II SMA, and 64% of patients with
type III SMA, identical numbers of Ag1-CA alleles and
SMN2 copies were found, whereas C212 alleles were
identical with SMN2 copies in 75% of patients with
type I SMA, 62% of patients with type II SMA, and
63% of patients with type III SMA, respectively. As ex-
pected, Ag1-CA showed a slightly higher correlation, on
the basis of its closer proximity to the 5′ end of the SMN
gene, than C212. In some cases, false interpretation of
the autoradiographies (duplicated alleles are sometimes
not easy to recognize) may be the cause of the discordant
data. However, these data also suggest that, at least in
part, incomplete deletions or duplications of SMN2 cop-
ies may be responsible for the discrepancies seen in
SMN2 copy number versus Ag1-CA/C212 alleles.
Furthermore, we checked for a correlation between
number of SMN2 copies and age of survival in 113
patients with type I SMA (fig. 4a). In 9 of 113 patients
with type I SMA, one SMN2 copy was found with a
median age of survival of 7 mo; none survived longer
than 11 mo. In 94 of 113 patients with type I SMA,
two SMN2 copies were found, with a median age of
survival of 8 mo. All but six patients with two SMN2
copies died before age 21 mo. In 10 of 113 patients,
three SMN2 copies were determined, with a median age
of survival of 37.5 mo; 8 of these 10 patients lived 33–66
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Table 5
Correlation between SMN2 Copy Number and Ag1-CA and
C212 Marker Alleles
POLYMORPHIC
MARKER,
TYPE OF SMA,
AND SMN2
COPY NUMBER
NO. OF MARKER ALLELESa
% OF
PATIENTSb1 2 3 4 5
Ag1-CA:
Type I SMA:
1 1 10 2
2 3 114 9 5 81
3 1 9 27
Type II SMA:
2 7 4 1
3 11 77 1 1 77
4 1 6 1
Type III SMA:
2 2 1
3 3 28 7 64
4 5 11 19
C212:
Type I SMA:
1 1 10 2
2 8 108 11 4 75
3 1 8 27 1
Type II SMA:
2 1 6 4 1
3 26 60 2 62
4 2 5 1
Type III SMA:
2 2 1
3 6 28 4 63
4 4 13 18
a Underlined, boldfaced numbers represent those values where
identical SMN2 copy number versus Ag1-CA/C212 alleles were
found.
b Percentage of patients with SMA with identical SMN2 copies
and Ag1-CA/C212 alleles.
mo, and 6 of those 8 also revealed three Ag1-CA alleles,
indicating that these patients with type I SMA owe their
increased survival to the increased number of SMN2
copies. On the basis of Kaplan-Meier survival curves,
we calculated the probability of survival for patients
with type I SMA in accordance with their SMN2 copy
number (fig. 4b).
Prediction of SMA Severity
Finally, we calculated the posterior probability of a
child with homozygous absence of SMN1 developing
type I, type II, or type III SMA, conditional on the num-
ber of SMN2 copies (table 6). A child with one SMN2
copy has a risk of 199%—and, with two SMN2 copies,
a risk of 97%—of developing type I SMA. A child with
three SMN2 copies has a risk of 82.8% of developing
type II SMA, and a child with four SMN2 copies has a
risk of 83.6% of developing type III SMA. These data
demonstrate nicely that SMN2 copy number can be used
as a prognostic tool.
Discussion
Here, we present the first quantitative test of SMN1 or
SMN2 based on real-time PCR by use of the LightCycler
Instrument. The possibility of direct measurement of the
PCR product accumulated after each cycle, without any
intermediate steps, ensures the high specificity of real-
time PCR assays. We succeeded in developing the test
so that gene-specific primers amplify only SMN1 but
not SMN2 (or vice versa).
SMN1 dosage analysis is frequently requested in the
context of genetic counseling, either as carrier testing
or as a means of identifying patients with compound
mutations (deletions and intragenic SMN1 mutation).
Unfortunately, the presence of two SMN1 copies per
chromosome or intragenic mutations in some of the
SMA chromosomes slightly diminishes the sensitivity of
the test (McAndrew et al. 1997; Wirth et al. 1999;
Scheffer et al. 2000; present study). On the basis of all
reported data, including this one, in 20/834 (2.4%)
healthy chromosomes, two SMN1 copies were found.
Consequently, 4.8% of normal individuals would be
misinterpreted as noncarriers on the basis of the direct
SMN1 test. The sensitivity of the test is 95.2%. In ad-
dition, 1.7% of SMA carriers reveal intragenic SMN1
mutations—given that 3.4% of patients with SMA
show compound SMN1 mutations, deletion plus intra-
genic mutation (Wirth et al. 1999)—and would not be
recognized by the SMN1 quantitative test. This reduces
the sensitivity of the test to 93.5% for a person from
the general population.
The quantification of SMN2 copies performed in this
paper in 375 patients with type I, type II, and type III
SMA demonstrates a significant correlation between
SMN2 copy number and type of SMA, as well as du-
ration of survival. Approximately 80% of patients with
type I SMA showed only one or two SMN2 copies,
suggesting that these patients mainly carry genuine de-
letions of SMN1, whereas SMN2 is present either on
one chromosome (genotype 0:1 or 0:2) or on both chro-
mosomes (genotype 1:1). Furthermore, for patients with
type I SMA, we were able to show an inverse correlation
between SMN2 copy number and duration of survival;
patients with one SMN2 copy had a median survival
of 7 mo, whereas those with two or three SMN2 copies
survived 8 and 37.5 mo, respectively. Although, in the
first months, the survival curves are relatively similar,
the probability of survival for type I patients with one
SMN2 copy is significantly lower than that for patients
with two SMN2 copies (fig. 4b). The median age of
survival for patients with one SMN2 copy might even
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Table 6
Probabilities That an Unaffected Child Who Has Been Tested after
Birth and Has Been Found to Carry a Homozygous Absence of
SMN1 Will Develop Type I, II, or III SMA, on the Basis of Number
of SMN2 Copies
PROBABILITY TYPE AND
NO. OF SMN2 COPIES
PROBABILITY OF
DEVELOPING SMA
Type I Type II Type III
Prior probabilities .51 .32 .17
Conditional probabilities (OR):a
One copy 1.00 !.001 !.001
Two copies 1.00 .044 .0145
Three copies 1.00 18.4 4.19
Four copies 1.00 14.7 156.7
Joint probabilities:
One copy .51 !.00032 !.00017
Two copies .51 .0141 .000255
Three copies .51 5.89 .712
Four copies .51 4.70 26.6
Posterior probabilities (%):
One copy 199.9 !.1 !.1
Two copies 97.26 2.7 .04
Three copies 7.2 82.8 10.0
Four copies 1.6 14.8 83.6
a The OR for one copy was used as a reference and was fixed to
unity.
Figure 4 a, Age of survival of children with type I SMA, correlated with the average SMN2 value. Circles correspond to one SMN2 copy,
squares to two SMN2 copies, and triangles to three SMN2 copies. The line represents a trendline for the age of survival versus the SMN2 copy
number. b, Kaplan-Meier curves show the probabilities of survival for patients with type I SMA who carry one, two, or three SMN2 copies.
be biased, given the inclusion criteria for the quanti-
tative analysis. We considered only those patients from
whom DNA was isolated by the same method. Patients
who died soon after birth had to be excluded sometimes,
since only small amounts of DNA or DNA from muscle
biopsies were available.
Our results of SMN2 copy number also fit well with
our previously reported SMAmodel (Wirth et al. 1995),
where we hypothesized that patients with type I SMA
carry two “severe” SMA chromosomes and that pa-
tients with type II SMA carry one “severe” and one
“mild” SMA chromosome, whereas patients with type
III SMA carry two “mild” SMA chromosomes. In∼80%
of patients with type I SMA, we identified one or two
SMN2 copies, corresponding to deletions of SMN1 on
both chromosomes. About 80% of patients with type
II SMA carry three SMN2 copies, corresponding to a
deletion of SMN1 on one chromosome and a gene con-
version of SMN1 in SMN2 on the second chromosome,
whereas ∼45% of patients with type III SMA showed
four SMN2 copies, corresponding to gene conversion
on both chromosomes.
In previous work, Burghes (1997) reported a quan-
titative analysis of SMN2 copies in 21 patients with
type I SMA, 38.1%, 42.9%, and 19% of whom had
SMN2 copy numbers of one, two, and three, respec-
tively, and in 58 patients with type II and type III SMA,
12%, 48.3%, 34.5%, and 5.2% of whom had SMN2
copy numbers of one, two, three, and four, respectively.
Since the number of patients with type I SMA is small
and the numbers of patients with type II and type III
SMA are not listed separately, it is difficult to compare
the data. Similarly, Taylor et al. (1998) performed a
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quantitative analysis of SMN2 in 26 patients with type
I SMA and 23 patients with type II or type III SMA
and showed a significant correlation between lower ra-
tios for SMN2 versus MPZ (control gene) in type I and
between higher ratios in type II and III. However, the
authors stated that they were unable to assess exact copy
number from those ratios.
The impressive progress achieved in the last few years
in the understanding of the molecular basis of SMA and
the recent identification of drugs that increase full-
length SMN2 mRNA open the possibility of a therapy
for patients with SMA in the near future. Quantification
of the SMN2 copies in patients with SMA will be an
essential prerequisite of therapy. Clinicians could start
therapy and adapt drug treatment depending on the
SMN2 copies before motor neurons are affected and
children show first symptoms.
Our data show that, although various factors—such
as modifying genes, external factors, intragenic SMN2
mutations, and incomplete SMN2 copies—can slightly
influence the SMA phenotype, the risk calculation for
a child with homozygous absence of SMN1 to develop
a type I, II or III SMA can be reliably predicted. This
study will open new diagnostic possibilities for routine
laboratories and will be essential in clinical trials in
patients with SMA.
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